Pathologists in Singapore adopt Philips Digital Pathology Solutions to enhance disease diagnoses

November 17, 2015

Singapore  Royal Philips (NYSE: PHG, AEX: PHIA) today announced the growing adoption of its Digital Pathology Solutions by health systems across the globe to address the increasing healthcare needs caused by aging population and complex diseases such as cancer. Through its IntelliSite Pathology Solution,* Philips enables health care organizations to digitize the traditional histopathology workflow, enhance efficiency and productivity, and improve the confidence in making diagnoses.


Through examination of patient tissue samples, pathology plays a crucial role in the diagnosis, management and prevention of a variety of diseases, including cancer. As health care cost and quality pressures continue to mount, digital pathology can help improve the efficiency and quality of diagnostics. Several high-volume and networked pathology institutions across the world have implemented the Philips digital pathology platform, which offers an integrated approach to improve workflows, enhance collaboration capabilities to speed up consults, unify patient data and enable a flexible growth path to get more information from tumor tissue.


Supporting archiving in Singapore General Hospital


Singapore General Hospital (SGH), the flagship hospital of the country’s public healthcare system, recently implemented the world’s largest digital pathology installation in its diagnostic laboratory. To handle its more than 50,000 pathology cases a year, SGH will leverage more than 1.6 petabytes of disk storage and 1.6 petabytes of tape archiving storage to avoid the challenges of storing glass tissue slides – like loss, breakage, degrading or manual archiving errors – and reduce the physical space needed to manage all of these records.


“As Singapore’s population continues to age, healthcare support for seniors becomes an important priority in our health agenda. Modern pathology labs are coming under continued pressure to increase throughput and efficiency in order to cope with the increasing demand of their services,” said Diederik Zeven, General Manager of Philips Health Systems, ASEAN Pacific.


“As the shift towards personalized medicine requires pathology data that guides the right therapy for the right patient at the right time, Philips is driving the evolution toward digitized workflows to ensure pathologists are empowered to meet industry demand.”


Across the globe, leading institutions are leveraging Philips’ experience in clinical digital transformation to help pathology laboratories make that next step in workflow improvement and accelerate knowledge sharing between care providers.


*Philips IntelliSite Pathology Solution is licenced for use in Singapore and is CE marked for primary diagnostics in the EU. In the U.S., Philips IntelliSite Pathology Solution is cleared by FDA for diagnostic use in the evaluation of HER2 expression in breast cancer and is offered for research use (RUO).

For further information, please contact:

Elaine Ng

Head of Communications

Philips ASEAN Pacific

Tel: +65 9455 2834



About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 106,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at